Preclinical Research on GHK-Cu and Cellular Regeneration Preclinical research on GHK-Cu explores fibroblasts, collagen, glycosaminoglycans, angiogenesis, inflammation, matrix metalloproteinases, tissue inhibitors, and wound models [4], [5], [10], [12]
Cancer history or active malignancy: The peptide angiogenic properties could theoretically promote tumor vascularization
TB-500 is commonly discussed as a synthetic fragment related to thymosin beta-4, a naturally occurring peptide involved in cell migration, actin regulation, and wound-healing biology
Recovery is about helping damaged tissue, whether from a hard training block or an injury, heal and calm down
Among the twelve peptides removed from the Category 2 list (effective April 23, 2026): Removal from Category 2 is separate from the FDAs review of which peptides may be compounded under section 503A